Palatin initiates clinical development program evaluating bremelanotide

Palatin Technologies announced it has initiated a clinical development program evaluating bremelanotide, a melanocortin receptor 4 agonist, co-formulated with a PDE5 inhibitor, for the treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy. Working with a collaborator, Palatin has developed a co-formulation of bremelanotide and a PDE5i which can be administered as a single injection. The initial trial for the clinical development program for this novel co-formulation will be a Phase 2 clinical study of bremelanotide co-administered with a PDE5i in ED patients who have not responded to PDE5i treatment. This study is currently expected to start in the fourth quarter of the calendar year 2023.